论文部分内容阅读
目的:比较奥卡西平与苯妥英钠对癫痫患者的临床疗效和安全性。方法:选取2014年6月—2015年6月间收治的癫痫患者80例,将其随机分为治疗组与对照组,每组40例;对照组患者给予苯妥英钠治疗,治疗组患者给予奥卡西平治疗,比较两组患者治疗后的总有效率和不良反应的发生率。结果:治疗后治疗组患者的总有效率为94.00%高于对照组为58.00%(P<0.05),不良反应的发生率为12.50%低于对照组为37.50%(P<0.05);两组患者不良反应症状未影响癫痫的临床疗效。结论:奥卡西平对癫痫患者的临床疗效优于苯妥英钠,且其不良反应的发生率较低。
Objective: To compare the clinical efficacy and safety of oxcarbazepine and phenytoin in patients with epilepsy. Methods: Totally 80 epilepsy patients were selected from June 2014 to June 2015. They were randomly divided into treatment group and control group, 40 cases in each group. Patients in the control group were given phenytoin sodium, Xiping treatment, comparing the two groups of patients after treatment, the total effective rate and the incidence of adverse reactions. Results: After treatment, the total effective rate of the treatment group was 94.00%, which was significantly higher than that of the control group (58.00%, P <0.05). The incidence of adverse reactions was 12.50% in the treatment group and 37.50% in the control group (P <0.05) Adverse symptoms of patients did not affect the clinical efficacy of epilepsy. Conclusion: The clinical efficacy of oxcarbazepine in patients with epilepsy is better than phenytoin sodium, and the incidence of adverse reactions is lower.